Towards evidence‐based integration of services for HIV, non‐communicable diseases and substance use: insights from modelling

Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-communicable diseases (NCDs) and new premium priced medicines for cancer, orphan diseases and other complex areas. This is difficult to sustain without reforms. Methods: Extensive narrative review of published papers and contextualizing the findings to provide future guidance. Results: New models are being introduced to improve the managed entry of new medicines including managed entry agreements, fair pricing approaches and monitoring prescribing against agreed guidance. Multiple measures have also successfully been introduced to improve the prescribing of established medicines. This includes encouraging greater prescribing of generics and biosimilars versus originators and patented medicines in a class to conserve resources without compromising care. In addition, reducing inappropriate antibiotic utilization. Typically, multiple measures are the most effective. Conclusion: Multiple measures will be needed to attain and retain universal healthcare.

Download Full-text

The contribution of Cyprus to non-communicable diseases and biomedical research from 2002 to 2013: implications for evidence-based health policy

Health Research Policy and Systems ◽

10.1186/s12961-018-0355-4 ◽

2018 ◽

Vol 16 (1) ◽

Cited By ~ 1

Author(s):

Elena Pallari ◽

Grant Lewison ◽

Chryso Th. Pallari ◽

George Samoutis ◽

Mursheda Begum ◽

...

Keyword(s):

Health Policy ◽

Biomedical Research ◽

Communicable Diseases ◽

Evidence Based ◽

Non Communicable Diseases

Download Full-text

Self-monitoring and treatment of chronic non-communicable diseases in the context of the COVID-19 pandemic. Consensus of experts of the National society of evidence-based pharmacotherapy and the Russian society of the prevention of non-communicable diseases

CARDIOVASCULAR THERAPY AND PREVENTION ◽

10.15829/1728-8800-2020-2567 ◽

2020 ◽

Vol 19 (3) ◽

pp. 2567

Author(s):

S. Yu. Martsevich ◽

N. P. Kutishenko ◽

Yu. V. Lukina ◽

S. N. Tolpygina ◽

L. P. Ivanova ◽

...

Keyword(s):

Communicable Diseases ◽

Evidence Based ◽

Russian Society ◽

National Society ◽

Close Attention ◽

Self Monitoring ◽

Non Communicable Diseases ◽

Recommended Treatment ◽

Coronavirus Infection ◽

Medical Recommendations

In the current epidemic of a new coronavirus infection, COVID-19 treatment of patients with chronic non-communicable diseases (NCDS) and cardiovascular diseases (CVD), in particular, requires close attention of doctors. The main objectives of such patients’ management tactics are to ensure that patients comply with self-isolation measures that prevent infection, motivate patients to follow all medical recommendations. Special attention should be paid to comply with recommended treatment of CVD. In the case of an infectious disease, it is necessary to assess the prescribed therapy for interaction with medications already taken by the patient. However, the tactics for COVID-19 therapy, including in patients with NCDS, may change over time, since there are currently no drugs with proven effectiveness for the treatment of a new coronavirus infection.

Download Full-text